Yayın:
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorÜskent, Necdet
dc.contributor.authorBurak Bi̇lgi̇n
dc.contributor.authorNail Paksoy
dc.contributor.authorSaadettin Kılıçkap
dc.contributor.authorMuhammed Mustafa Atçı
dc.contributor.authorSeda Kahraman
dc.contributor.authorMerve Keskinkılıç
dc.contributor.authorİrem Bilgetekin
dc.contributor.authorMurat Ayhan
dc.contributor.authorDeniz Tural
dc.contributor.authorÖnder Eren
dc.contributor.authorFatma Nihan Akkoç Mustafayev
dc.contributor.authorŞebnem Yaman
dc.contributor.authorAli Murat Tatlı
dc.contributor.authorErtuğrul Bayram
dc.contributor.authorYasin Kutlu
dc.contributor.authorİsmail Ertürk
dc.contributor.authorErkan Özcan
dc.contributor.authorAhmet Gülmez
dc.contributor.authorMustafa Korkmaz
dc.contributor.authorBaran Akagündüz
dc.contributor.authorDi̇lek Erdem
dc.contributor.authorTuğba Akın Telli
dc.contributor.authorAsude Aksoy
dc.contributor.authorNecdet Üskent
dc.contributor.authorYakup İriağaç
dc.contributor.authorNaziyet Köse Baytemür
dc.contributor.authorDinçer Aydın
dc.contributor.authorTeoman Şakalar
dc.contributor.authorHacı Arak
dc.contributor.authorFatih Selçukbırıcık
dc.contributor.authorYakup Ergün
dc.contributor.authorTaner Korkmaz
dc.contributor.authorNaziye Ak
dc.contributor.authorÇağlar Ünal
dc.contributor.authorNadiye Akdeniz
dc.contributor.authorMehmet Alpaslan Özgün
dc.contributor.authorBerna Öksüzoğlu
dc.contributor.authorBülent Yalçın
dc.contributor.authorİlhan Öztop
dc.contributor.authorEfnan Algın
dc.contributor.authorAbdullah Sakin
dc.contributor.authorAdnan Aydıner
dc.contributor.authorPerran Fulden Yumuk
dc.contributor.authorMehmet Alı Nahıt Şendur
dc.contributor.orcid0000-0001-5147-4431
dc.contributor.orcid0000-0003-1717-8246
dc.contributor.orcid0000-0003-4636-2595
dc.contributor.orcid0000-0003-1637-7390
dc.contributor.orcid0000-0002-1300-3695
dc.contributor.orcid0000-0002-5328-6554
dc.contributor.orcid0000-0002-3342-3144
dc.contributor.orcid0000-0003-1154-5850
dc.contributor.orcid0000-0002-0631-4006
dc.contributor.orcid0000-0003-2144-6469
dc.contributor.orcid0000-0001-7024-4156
dc.contributor.orcid0000-0001-9696-1102
dc.contributor.orcid0000-0001-8713-7613
dc.contributor.orcid0000-0003-2184-634X
dc.contributor.orcid0000-0001-6835-0988
dc.contributor.orcid0000-0003-1562-6340
dc.contributor.orcid0000-0002-3353-344X
dc.contributor.orcid0000-0003-0926-6748
dc.contributor.orcid0000-0002-4979-3123
dc.contributor.orcid0000-0001-6495-6712
dc.contributor.orcid0000-0001-6535-6030
dc.contributor.orcid0000-0002-5609-9658
dc.contributor.orcid0000-0003-2739-7362
dc.contributor.orcid0000-0001-7411-1705
dc.contributor.orcid0000-0002-3587-2517
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0002-2023-423X
dc.contributor.orcid0000-0002-1273-1674
dc.contributor.orcid0000-0003-4784-6743
dc.contributor.orcid0000-0003-4292-0545
dc.contributor.orcid0000-0001-5790-7066
dc.contributor.orcid0000-0003-3245-1570
dc.contributor.orcid0000-0002-4597-9721
dc.contributor.orcid0000-0002-2756-8646
dc.contributor.orcid0000-0002-4431-8948
dc.contributor.orcid0000-0002-0425-0651
dc.contributor.orcid0000-0002-8917-9267
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0002-1104-5840
dc.contributor.orcid0000-0001-8650-299X
dc.contributor.orcid0000-0001-7021-6139
dc.date.accessioned2025-11-13T11:01:51Z
dc.date.issued2022-06-23
dc.identifier.doihttps://doi.org/10.2217/fon-2022-0083
dc.identifier.endpage2582
dc.identifier.issn1479-6694
dc.identifier.issue23
dc.identifier.openalexW4283367181
dc.identifier.startpage2573
dc.identifier.urihttps://hdl.handle.net/11421/6000
dc.identifier.urihttps://doi.org/10.2217/fon-2022-0083
dc.identifier.volume18
dc.language.isoen
dc.relation.ispartofFuture Oncology
dc.rightsrestrictedAccess
dc.subjectAlectinib
dc.subjectMedicine
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectLung cancer
dc.subjectStage (stratigraphy)
dc.subjectProgression-free survival
dc.subjectCeritinib
dc.subjectChemotherapy
dc.subjectCrizotinib
dc.subject.sdg3
dc.titleReal-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5064757657

Dosyalar

Koleksiyonlar

Publications